Luminar Media Group, Inc., and The Jenex Corporation report the completion of a working prototype for the patent pending TherOZap™ device. An Agreement has been signed with the University Health Network to test Therozap™ against the Zika and West Nile viruses. Jenex has optimized the features on the TherOZap™ working prototype device as protection against both the Zika virus and West Nile virus and potentially other mosquito borne diseases.

Jenex has signed an agreement with University Health Network (“UHN”) to initiate testing of the TherOZap™ device against these viruses. Over the next several weeks Jenex will be coordinating with the Techna Institute at UHN to devise the protocols for the initial tests. It is anticipated that once all testing is complete, Jenex will commercialize TherOZap™, pending regulatory approval where required.